Copper-64-labeled antibodies for PET imaging

C. J. Anderson, J. M. Connett, S. W. Schwarz, P. A. Rocque, Wu Guo Li Wu Guo, G. W. Philpott, K. R. Zinn, C. F. Meares, M. J. Welch

Research output: Contribution to journalArticle

138 Scopus citations

Abstract

In the imaging of tumors using radiolabeled monoclonal antibodies, the use of PET gives increased sensitivity over conventional gamma camera imaging techniques. Copper-64, a positron-emitting radionuclide, has been labeled to 1A3, an anticolorectal carcinoma monoclonal antibody, and its fragments 1A3- F(ab')2 utilizing the bifunctional chelate Br-benzyl-TETA. The 64Cu- labeled intact 1A3 and 1A3-F(ab')2 have been evaluated as potential imaging agents for PET. Biodistribution studies of 64Cu-benzyl-TETA-1A3 and 64Cu- benzyl-TETA-1A3-F(ab')2 in tumor-bearing hamsters were compared with those of 111In-BrΦHBED-1A3, 111In-BrΦHBED-1A3-F(ab')2 and 126I-labeled intact 1A3 and 1A3-F(ab')2. Tumor uptake of 64Cu-labeled intact 1A3 and fragments in the hamster model was superior to both 111In- and 125I- labeled intact 1A3 and fragments. Human dosimetry data for 64Cu- and 123I-labeled 1A3 and 1A3-F(ab')2 were calculated from biodistribution data in rats. High kidney uptake of 64Cu-benzyl-TETA-1A3-F(ab')2 precludes clinical study at this time; however, the data shows that 64Cu-benzyl-TETA- 1A3 would be suitable for positron tomography imaging of colorectal cancer in patients.

Original languageEnglish (US)
Pages (from-to)1685-1691
Number of pages7
JournalJournal of Nuclear Medicine
Volume33
Issue number9
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'Copper-64-labeled antibodies for PET imaging'. Together they form a unique fingerprint.

  • Cite this

    Anderson, C. J., Connett, J. M., Schwarz, S. W., Rocque, P. A., Li Wu Guo, W. G., Philpott, G. W., Zinn, K. R., Meares, C. F., & Welch, M. J. (1992). Copper-64-labeled antibodies for PET imaging. Journal of Nuclear Medicine, 33(9), 1685-1691.